Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm presents safety, updated pivotal data at European League Against Rheumatism meeting. BLA submission for the first-in-class rheumatoid arthritis biologic was completed in March.
You may also be interested in...
Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says
FDA's Arthritis Drugs Advisory Committee unanimously recommends approval of the rheumatoid arthritis therapy abatacept.
Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says
FDA's Arthritis Drugs Advisory Committee unanimously recommends approval of the rheumatoid arthritis therapy abatacept.
Bristol Abatacept Infection, Malignancy Risk To Be Considered By Advisory Committee
Arthritis committee is expected to discuss the increased risk of infections when Orencia (abatacept) is used in combination with other biologic rheumatoid arthritis therapies during the Sept. 6 review of Bristol's drug.